Abstract: Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
August 24, 2021
Assignee:
Research Development Foundation
Inventors:
J. Timothy Stout, Binoy Appukuttan, Trevor McFarland
Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity.
Abstract: The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
August 10, 2021
Assignee:
University of Washington through its Center for Commercialization
Inventors:
Robert A. Steiner, Charles Chavkin, Donald K. Clifton, Susan Reed, Victor Navarro
Abstract: The present invention relates to methods of treating a subject suffering from or at risk of suffering from graft versus host disease (GvHD) comprising administering a therapeutically effective amount of at least one of pregnancy specific glycoprotein 1 (PSG1) or PSG9 to a subject in need thereof.
Type:
Grant
Filed:
September 16, 2016
Date of Patent:
May 18, 2021
Assignees:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
May 11, 2021
Assignee:
Wellstat ImmunoTherapeutics, LLC
Inventors:
ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.
Type:
Grant
Filed:
April 4, 2017
Date of Patent:
May 11, 2021
Assignees:
VIB VZW, UniversiteitGent
Inventors:
Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
Abstract: The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
Type:
Grant
Filed:
August 14, 2015
Date of Patent:
April 6, 2021
Assignees:
PFIZER INC., RINAT NEUROSCIENCE CORP.
Inventors:
Russell George Dushin, Pavel Strop, Magdalena Grazyna Dorywalska, Ludivine Moine
Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 40% of the hemoglobin in the composition is provided in CO-charged form.
Abstract: Described herein are cyclic peptides, nanoparticles bound with cyclic peptides, and methods for using said cyclic peptides and/or said nanoparticles bound with cyclic peptides for intraoperative nerve tissue imaging.
Type:
Grant
Filed:
May 17, 2019
Date of Patent:
March 9, 2021
Assignees:
Cornell University, Memorial Sloan Kettering Cancer Center
Inventors:
Michelle S. Bradbury, Barney Yoo, Ulrich Wiesner, Peiming Chen, Kai Ma, Snehal G. Patel, Daniella Karassawa Zanoni
Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.
Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.
Abstract: The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods of the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody.
Type:
Grant
Filed:
August 8, 2016
Date of Patent:
December 15, 2020
Assignee:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Inventors:
John Matthew Koomen, Elizabeth Renee Remily, Kaaron Benson, Mohamad Hussein
Abstract: Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.
Type:
Grant
Filed:
January 23, 2020
Date of Patent:
December 15, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
December 1, 2020
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Mark Thomas Gladwin, Jesus Tejero Bravo
Abstract: A phosphatidylserine targeted peptoid has been identified with the ability to bind to cancer cells globally and specifically. A dimer of the peptoid decreases cancer cell viability. Use of the dimerized peptoid enhances the efficacy of docetaxel. The peptoid can be used for including but not limited to diagnosing and treating cancer, diagnosing and treating a viral condition, and diagnosing and treating diabetes.
Type:
Grant
Filed:
July 23, 2016
Date of Patent:
December 1, 2020
Assignees:
University of Houston System, Board of Regents of The University of Texas System
Inventors:
Damith Gomika Udugamasooriya, Rolf A. Brekken